Research programme: ocular therapeutics - Santen Pharmaceutical/twoXAR

Drug Profile

Research programme: ocular therapeutics - Santen Pharmaceutical/twoXAR

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator twoXAR
  • Developer Santen Pharmaceutical; twoXAR
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Glaucoma

Most Recent Events

  • 23 Feb 2017 Early research in Glaucoma in Japan (unspecified route)
  • 23 Feb 2017 Santen and twoXAR enter into a collaboration for the identification of new drug candidates for glaucoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top